Physician profile
David Lefkowitz
NPI 1134273105
$3,529.12
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $289 · 2021: $37.52 · 2022: $723 · 2023: $813 · 2024: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $933.54 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $424.80 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $353.34 | 2019-2024 | |
| Atricure, INC. | $335.71 | 2022 | |
| Medtronic Vascular, INC. | $303.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.43 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.65 | 2019-2022 | |
| Boston Scientific Corporation | $138.75 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $118.62 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $95.57 | 2019-2023 | Eliquis |
| Esperion Therapeutics, INC. | $78.91 | 2021-2023 | Nexletol |
| Novo Nordisk INC | $76.64 | 2023-2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $69.15 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $51.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.94 | 2024 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $39.08 | 2023-2024 | Inpefa |
| Lundbeck LLC | $24.37 | 2019 | |
| Allergan, INC. | $24.35 | 2019 | |
| Pfizer INC. | $21.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.73 | 2020 | |
| Biotronik INC. | $19.51 | 2024 | Acticor 7 Vr-T Dx |
| Abbvie INC. | $16.93 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.